An interventional study of Fourier Domain Doppler Optical Coherence Tomography (FDOCT) and Dynamic Vessel Analyzer (DVA) in Glaucoma, Open-Angle, Normal Tension Glaucoma and Ocular Hypertension, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by Medical University of Vienna · Not applicable, Interventional, and Basic science
Glaucoma is characterized by a progressive loss of retinal ganglion cells (RGCs) leading to optic nerve head (ONH) damage and associated visual field defects. The main risk factor for glaucoma is elevated intraocular pressure (IOP). Reducing IOP slows down the progression of the disease as several large multicenter trials have shown. Some patients, however, still progress despite adequately controlled IOP. As such, there is considerable interest in approaches that rescue RGCs independent of IOP, a strategy called neuroprotection. Although this field was actively discovered in the last 20 years in the brain and the eye, no non-IOP related treatment is clinically available to date. Various approaches are currently studied in some detail. One interesting strategy focuses on the neurovascular unit.
The blood flow of the human retina is controlled by complex mechanisms that include myogenic, metabolic and hormonal factors. The high consumption of oxygen in the human retina is crucial for normal functioning of the organ. As in the brain, blood flow in the retina is also controlled by neurovascular coupling. This means that the retina increases its blood flow to regions in which neurons are activated. This is done in an effort to provide more oxygen and glucose to the active neurons. In the recent years evidence has accumulated that astrocytes play a key role in mediating this vasodilator signal.
In the brain, abnormalities in neurovascular coupling have been observed in diseases like stroke, hypertension, spinal-cord injury and Alzheimer's disease. This break-down of neurovascular coupling is considered to play a key role in neuronal death in these diseases. In the retina, abnormalities in neurovascular coupling have been observed in diseases as diabetes and glaucoma.
Most of the data obtained in the human retina stem from a system that measures retinal vasodilatation during stimulation with flickering light. The investigators have previously shown that flicker stimulation of the retina is, however, also associated with a pronounced increase in retinal blood velocities. In this study the investigators employed laser Doppler velocimetry (LDV) for the measurement of retinal blood velocities, but this technique is not clinically applicable because it requires excellent fixation of the subject under study. In the present study, the investigators propose to use an alternative system for neurovascular coupling that they have developed recently. In this approach, the investigators use bi-directional Fourier-domain optical coherence tomography for the assessment of retinal blood flow. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology, OCT has become a standard tool in visualizing the retina and nowadays is considered also as a standard tool in the diagnosis of retinal disease. In the recent years, conventional time domain OCT was replaced by Fourier domain OCT providing significantly improved signal quality.
This bidirectional system overcomes the limitations of previously realized techniques, which include doubtful validity and limited reproducibility. In addition, pattern ERG, multifocal ERG and oscillatory potentials will be measured to allow for concomitant assessment of neural function.
The investigators seek to measure neurovascular coupling in the human retina in patients with early primary open angle glaucoma (POAG), normal tension glaucoma, ocular hypertension and a healthy control group. In order to obtain information on neurovascular coupling, both neuronal function as well as retinal blood flow need to be measured. In the present study, the investigators will employ pattern ERG, multifocal ERG as well as oscillatory potentials to assess the function of the inner retina. Retinal blood flow through major retinal arterial and venous branch vessels will be measured before, during and after flicker stimulation with the dual-beam bidirectional Fourier Domain Doppler OCT coupled to the commercially available Dynamic Vessel Analyzer (DVA) produced by IMEDOS, Jena, Germany, which provides adequate resolution to study the retinal circulation.
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's planned enrollment of 120 is above the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →Medical University of Vienna is the lead sponsor of 1,076 studies on the registry; 177 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with primary open angle glaucoma
Patients with normal tension glaucoma
Patients with ocular hypertension
Healthy control subjects
Exclusion criteria
patients with primary open angle glaucoma with MD in visual field less than or equal 10dB
Device: Fourier Domain Doppler Optical Coherence Tomography (FDOCT) · Device: Dynamic Vessel Analyzer (DVA) · Device: Pattern Electroretinography (pERG) · Device: Optical coherence tomography (OCT) · Device: Laser Speckle Flowgraphy (LSFG)
patients with primary open angle glaucoma with MD in visual field more than 10dB
Device: Fourier Domain Doppler Optical Coherence Tomography (FDOCT) · Device: Dynamic Vessel Analyzer (DVA) · Device: Pattern Electroretinography (pERG) · Device: Optical coherence tomography (OCT) · Device: Laser Speckle Flowgraphy (LSFG)
patients with normal tension glaucoma with MD in visual field less than or equal 10dB
Device: Fourier Domain Doppler Optical Coherence Tomography (FDOCT) · Device: Dynamic Vessel Analyzer (DVA) · Device: Pattern Electroretinography (pERG) · Device: Optical coherence tomography (OCT) · Device: Laser Speckle Flowgraphy (LSFG)
patients with normal tension glaucoma with MD in visual field more than 10dB
Device: Fourier Domain Doppler Optical Coherence Tomography (FDOCT) · Device: Dynamic Vessel Analyzer (DVA) · Device: Pattern Electroretinography (pERG) · Device: Optical coherence tomography (OCT) · Device: Laser Speckle Flowgraphy (LSFG)
patients with ocular hypertension
Device: Fourier Domain Doppler Optical Coherence Tomography (FDOCT) · Device: Dynamic Vessel Analyzer (DVA) · Device: Pattern Electroretinography (pERG) · Device: Optical coherence tomography (OCT) · Device: Laser Speckle Flowgraphy (LSFG)
healthy, age and sex matched, control subjects
Device: Fourier Domain Doppler Optical Coherence Tomography (FDOCT) · Device: Dynamic Vessel Analyzer (DVA) · Device: Pattern Electroretinography (pERG) · Device: Optical coherence tomography (OCT) · Device: Laser Speckle Flowgraphy (LSFG)
Retinal blood flow will be assessed using FDOCT
Retinal vessel diameters and oxygen saturation will be measured with the DVA device
to assess the neuronal function of the retina, pattern ERG will be performed
to assess the morphology of the retina, OCT will be performed
to assess retinal blood flow, LSFG will be performed
Flicker induced blood flow alterations
Response of retinal blood flow to flicker light
Time frame: 1 day
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna